Part 2: Structure–activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38α mitogen-activated protein kinase

• Published in: Bioorganic & medicinal chemistry letters 2010-03, Vol.20 (5), p.1680-1684
• Main Authors: Wurz, Ryan P., Pettus, Liping H., Henkle, Bradley, Sherman, Lisa, Plant, Matthew, Miner, Kent, McBride, Helen J., Wong, Lu Min, Saris, Christiaan J.M., Lee, Matthew R., Chmait, Samer, Mohr, Christopher, Hsieh, Faye, Tasker, Andrew S.
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Bones, joints and connective tissue. Antiinflammatory agents; MAP kinase; Medical sciences; p38; Pharmacology. Drug treatments; Pyrazolopyridazine; TNF
• ISSN: 0960-894X; 1464-3405
• DOI: 10.1016/j.bmcl.2010.01.059

A novel class of pyrazolopyridazine p38α mitogen-activated protein kinase (MAPK) inhibitors is disclosed. A structure activity relationship (SAR) investigation was conducted driven by the ability of these compounds to inhibit the p38α enzyme, the secretion of TNFα in a LPS-challenged THP1 cell line and TNFα-induced production of IL-8 in the presence of 50% human whole blood (hWB). This study resulted in the discovery of several inhibitors with IC 50 values in the single-digit nanomolar range in hWB. Further investigation of the pharmacokinetic profiles of these lead compounds led to the identification of three potent and orally bioavailable p38α inhibitors 2h, 2m, and 13h. Inhibitor 2m was found to be highly selective for p38α/β over a panel of 402 other kinases in Ambit screening, and was highly efficacious in vivo in the inhibition of TNFα production in LPS-stimulated Lewis rats with an ED 50 of ca. 0.08 mg/kg.